<DOC>
	<DOCNO>NCT01323985</DOCNO>
	<brief_summary>The purpose study provide safety information define optimal induction short term maintenance regimen GSK2315698 deplete circulate SAP healthy volunteer prior assess patient</brief_summary>
	<brief_title>SAP Depleter Dose Escalation Study Healthy Volunteers</brief_title>
	<detailed_description>This single centre , open label , dose escalation study design assess safety ( include adverse event , vital sign , ECGs , clinical laboratory test ) , pharmacokinetic /pharmacodynamic parameter healthy volunteer . Subjects attend 3 session : session 1 single intravenous ( IV ) infusion short time period confirm safety single dose GSK2315698 wide dose range , session 2 3 investigate IV infusion regimens 24 hour ( induction phase follow maintenance phase ) . The dose regimen adjust adaptively optimise induction maintenance phase dose regimen . amyloidosis .</detailed_description>
	<mesh_term>Amyloidosis</mesh_term>
	<criteria>AST , ALT , alkaline phosphatase bilirubin great equal 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter outside reference range population study may include Investigator GSK Medical Monitor agree find unlikely introduce additional risk factor interfere study procedure . Male female 18 65 year age inclusive , time signing informed consent . A female subject eligible participate nonchildbearing potential define premenopausal female document tubal ligation hysterectomy ; postmenopausal define 12 month spontaneous amenorrhea [ questionable case blood sample simultaneous follicle stimulate hormone ( FSH ) &gt; 40 MlU/ml estradiol &lt; 40 pg/ml ( &lt; 147 pmol/L ) confirmatory ] . ( As precaution pregnancy test conduct prior dose ; positive test lead exclusion ) . Male subject female partner childbearing potential must agree use one contraception method list Protocol Section 8.1 . This criterion must follow time first dose study medication 85 day postlast dose . Body weight gretaer equal 50 kg BMI within range 19 30 kg/m2 ( inclusive ) . Capable give write informed consent , include compliance requirement restriction list consent form . Average QTc , &lt; 450 msec Peripheral vein suitable venous blood sample cannulation Smokers ( &lt; 10 /day ) permit must willing abstain duration residential study session A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . A positive prestudy drug/alcohol screen . A positive test HIV antibody . History regular alcohol consumption within 6 month study define : An average weekly intake &gt; 21 unit male &gt; 14 unit female . One unit equivalent 8 g alcohol : halfpint ( ~240 ml ) beer , 1 glass ( 125 ml ) wine 1 ( 25 ml ) measure spirit . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 3 month , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Previous surgical procedure upper digestive tract include cholecystectomy ( gallbladder removal ) , and/or cholelithotomy ( gallstone removal ) . Where participation study would result donation blood blood product excess 500 mL within 84 day period . Unwillingness inability follow procedure outline protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2011</verification_date>
</DOC>